Literature DB >> 10958784

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

T G Kroll1, P Sarraf, L Pecciarini, C J Chen, E Mueller, B M Spiegelman, J A Fletcher.   

Abstract

Chromosomal translocations that encode fusion oncoproteins have been observed consistently in leukemias/lymphomas and sarcomas but not in carcinomas, the most common human cancers. Here, we report that t(2;3)(q13;p25), a translocation identified in a subset of human thyroid follicular carcinomas, results in fusion of the DNA binding domains of the thyroid transcription factor PAX8 to domains A to F of the peroxisome proliferator-activated receptor (PPAR) gamma1. PAX8-PPARgamma1 mRNA and protein were detected in 5 of 8 thyroid follicular carcinomas but not in 20 follicular adenomas, 10 papillary carcinomas, or 10 multinodular hyperplasias. PAX8-PPARgamma1 inhibited thiazolidinedione-induced transactivation by PPARgamma1 in a dominant negative manner. The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958784     DOI: 10.1126/science.289.5483.1357

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  203 in total

1.  Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21.

Authors:  J D McKay; F Lesueur; L Jonard; A Pastore; J Williamson; L Hoffman; J Burgess; A Duffield; M Papotti; M Stark; H Sobol; B Maes; A Murat; H Kääriäinen; M Bertholon-Grégoire; M Zini; M A Rossing; M E Toubert; F Bonichon; M Cavarec; A M Bernard; A Boneu; F Leprat; O Haas; C Lasset; M Schlumberger; F Canzian; D E Goldgar; G Romeo
Journal:  Am J Hum Genet       Date:  2001-07-02       Impact factor: 11.025

2.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).

Authors:  C A French; I Miyoshi; J C Aster; I Kubonishi; T G Kroll; P Dal Cin; S O Vargas; A R Perez-Atayde; J A Fletcher
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 3.  The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia.

Authors:  Simon J Raphael
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 4.  Tumors of thyroid follicular epithelium: where have we been and where are we going?.

Authors:  Arthur S Tischler; Ronald A DeLellis
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 5.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

Review 6.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 7.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

8.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Tália Feijão; Ana Paula Rebocho; Elsa Fonseca; Inês Vieira de Castro; José Cameselle-Teijeiro; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2004-04-17       Impact factor: 4.064

Review 10.  Oncogenic gene fusions in epithelial carcinomas.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Curr Opin Genet Dev       Date:  2009-02-21       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.